Payers wade into real-world evidence, but tread lightly

Thursday, 01 February 2018

“Payers have to be convinced that the data is accurate and that the population in whom the data exists is representative of the membership of their beneficiaries,” Kolodziej said, now vice president and chief innovation officer at ADVI, a consultancy. “They don’t want ineffective therapies that are toxic and expensive to be given to the rotation. So I think that’s the line they’re walking.”

[/el-text]

View full article here